Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

US10995150B2 · kind B2 · utility

Assignees

• REGENERON PHARMACEUTICALS, INC. · US
• SANOFI BIOTECHNOLOGY · FR

Inventors

• William J. Sasiela · Tarrytown, US
• Viktoria Gusarova · Pleasantville, US
• Anusch Peyman · Frankfurt am Main, DE
• Hans-Ludwig Schafer · Hochheim, DE
• Uwe Schwahn · Frankfurt am Main, DE

Key dates

• Filing date: Jul 8, 2019
• Grant date: May 4, 2021
• Expiry date: Jul 8, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.